NEOPLASMS
Clinical trials for NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NEOPLASMS trials appear
Sign up with your email to follow new studies for NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for common lung cancer
Disease control OngoingThis study looks at how well a combination of osimertinib (a targeted drug) and chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. About 532 adults with stage IIIB/IV or recurrent disease are being followed in real-world cli…
Matched conditions: NEOPLASMS
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 28, 2026 23:51 UTC
-
Cancer patients get continued access to promising targeted therapy
Disease control OngoingThis study offers ongoing treatment with alectinib or crizotinib to people with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The goal is to keep providing the medication safely while monitoring side effects and survival. Abou…
Matched conditions: NEOPLASMS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 28, 2026 23:50 UTC
-
Bridge study offers lifeline for cancer patients on atezolizumab
Disease control OngoingThis study allows cancer patients who were already benefiting from atezolizumab in a previous Roche-sponsored trial to keep receiving the drug if they have no other local options. It includes 49 participants and focuses on safety and continued treatment access. The goal is to ens…
Matched conditions: NEOPLASMS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer that has not responded to standard treatments. The study has two parts: the first finds the safest dose of BI 765179 alone or with another drug (ezabenlim…
Matched conditions: NEOPLASMS
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 28, 2026 13:01 UTC